Immunisation of adolescents in the UK

Archives of Disease in Childhood

Volumn 96, Issue 5, 2011, Pages 492-495

  Kale, Ashutosh R ^a   Snape, Matthew D ^b  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TETANUS VACCINE; DIPHTHERIA VACCINE; HEMAGGLUTININ; HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PERTACTIN; PERTUSSIS VACCINE; POLIOMYELITIS VACCINE; TETANUS TOXOID; WART VIRUS VACCINE;

ADOLESCENT HEALTH; BORDETELLA PERTUSSIS; CHILD HEALTH CARE; DIPHTHERIA; DISEASE TRANSMISSION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MENINGOCOCCEMIA; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; PERTUSSIS; POLIOMYELITIS; PRIORITY JOURNAL; REVIEW; TETANUS; UNITED KINGDOM; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; FEMALE; GREAT BRITAIN; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; MALE; MENINGITIS, MENINGOCOCCAL; PAPILLOMAVIRUS VACCINES; PERTUSSIS VACCINE;

EID: 79954624170     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2010.196667     Document Type: Review

References (64)

1. Viner RM, B arker M. Young people's health: the need for action. BMJ 2005;330:901-3.
2. National Service Framework: Management of Adolescent Health in Primary Care. http://www.pcc.nhs.uk/uploads/primary-care-service-frameworks/primary- care-service-framework---adolescent-health.pdf (accessed 8 June 2009).
3. Annual HPV vaccine uptake in England: 2008/09. http://www.dh.gov.uk/ prod-consum-dh/groups/dh-digitalassets/@dh/@en/@ps/documents/digitalasset/ dh-111676.pdf (accessed on 1 July 2010).
4. Brabin L, Roberts SA, Stretch R, et al. Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 2008;336:1056-8. (Pubitemid 351692248)
5. NHS Immunisation Statistics England 2008-09. http://www.ic.nhs.uk/ webfiles/ publications/003-Health-Lifestyles/immstats2008-2009/Final-Imms- Bulletin-2008-09- Updated27Oct10.pdf (accessed 15 Sep 2010).
6. Forsyth KD, Wirsing von Konig CH, Tan T, et al. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007;25:2634-42. (Pubitemid 46400927)
7. Brabin L, Greenberg DP, Hessel L, et al. Current issues in adolescent immunization. Vaccine 2008;26:4120-34.
8. Ranganathan S, Tasker R, Booy R, et al. Pertussis is increasing in unimmunized infants: is a change in policy needed? Arch Dis Child 1999;80:297-9.
9. Baron S, Njamkepo E, Grimprel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 1998;17:412-8.
10. Isacson J, Trollfors B, Hedvall G, et al. Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis. Scand J Infect Dis 1995;27:273-7.
11. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 2000;38:800-6. (Pubitemid 30082684)
12. Heininger U, Cherry JD, Stehr K. Serologic response and antibody-titer decay in adults with pertussis. Clin Infect Dis 2004;38:591-4. (Pubitemid 38250973)
13. Giuliano M, Mastrantonio P, Giammanco A, et al. Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Dev Biol Stand 1997;89:275-8.
14. Zorzeto TQ, Higashi HG, da Silva MT, et al. Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin Vaccine Immunol 2009;16:544-50.
15. Aoyama T, Harashima M, Nishimura K, et al. Outbreak of pertussis in highly immunized adolescents and its secondary spread to their families. Acta Paediatr Jpn 1995;37:321-4.
16. Cattaneo LA, Reed GW, Haase DH, et al. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years. J Infect Dis 1996;173:1256-9. (Pubitemid 26251472)
17. Health Protection Agency: Laboratory confirmed cases of pertussis infection England and Wales, by age 2002-2008. http://www.hpa.org.uk/webw/ HPAweb&HPAwebStandard/HPAweb-C/1195733779917?p=1191942148402 (accessed 24 November 2010).
18. Health Protection Weekly Report: Volume 2;No. 48 Published 28 November 2008. http://www.hpa.org.uk/hpr/archives/2008/hpr4808.pdf (accessed 30 November 2009).
19. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005;18:326-82. (Pubitemid 40548297)
20. Brooks DA, Clover R. Pertussis infection in the United States: role for vaccination of adolescents and adults. J Am Board Fam Med 2006;19:603-11. (Pubitemid 44736815)
21. Campins-MartíM, Cheng HK, Forsyth K, et al. International Consensus Group on Pertussis Immunisation. Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 2001;20:641-6.
22. Miller E, Fleming DM, Ashworth LA, et al. Serological evidence of pertussis in patients presenting with cough in general practice in Birmingham. Commun Dis Public Health 2000;3:132-4.
23. Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis 2001;183:1353-9.
24. Deen JL, Mink CA, Cherry JD, et al. Household contact study of Bordetella pertussis infections. Clin Infect Dis 1995;21:1211-9.
25. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004;23:985-9.
26. Wilson TR. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis. J Pediatr Health Care 2006;20:229-37. (Pubitemid 44007081)
27. Centers for Disease Control and Prevention/vaccines/programs. http://www.cdc. gov/vaccines/programs/vmbip/downloads/agm/bt-fda-apr.doc (accessed 25 January 2010).
28. US Food and Drug Administration: Adacel (January 2009) http://www.fda.gov/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172481. htm (accessed 25 January 2010).
29. Southern J, Andrews N, Burrage M, et al. Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine 2005;23:3829-35. (Pubitemid 40704747)
30. Barreto L, Guasparini R, Meekison W, et al. Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine 2007;25:8172-9. (Pubitemid 350046319)
31. Bailleux F, Coudeville L, Kolenc-Saban A, et al. Predicted long-term persistence of pertussis antibodies in adolescents after an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine, based on mathematical modeling and 5-year observed data. Vaccine 2008;26:3903-8.
32. Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005;293:3003-11. (Pubitemid 40965070)
33. Tran Minh NN, He Q, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 1999;104:e70.
34. Daum RS, Marshall G, Walter E, et al. Immunogenicity of tetanus-diphtheria-acellular pertussis (Tdap) vaccine in adolescents. Abstract presented at the American Academy of Pediatrics Conference and Exhibition, October 2004, San Francisco, USA
35. Van der Wielen M, Van Damme P, Joossens E, et al. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 2000;18:2075-82. (Pubitemid 30129096)
36. Committee on Infectious Diseases, American Academy of Paediatrics. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (tdap) vaccine. Pediatrics 2006;117:965-78.
37. Heininger U. Pertussis immunisation in adolescents and adults. Adv Exp Med Biol 2008;609:72-97.
38. Health Protection Report: Immunisation; Volume 4, No. 38 http://www.hpa.org.uk/ hpr/infections/immunisation.htm (accessed 1 July 2010).
39. Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008;336:1487-91. (Pubitemid 351977021)
40. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009;9:213-20.
41. Trotter CL, Borrow R, Findlow J, et al. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era. Clin Vaccine Immunol 2008;15:1694-8.
42. Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 2010;50:1601-10.
43. Tully J, Viner RM, Coen PG, et al. Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ 2006;332:445-50.
44. Harrison LH, Kreiner CJ, Shutt KA, et al. Meningococcal High School Study Group. Risk factors for meningococcal disease in students in grades 9-12. Pediatr Infect Dis J 2008;27:193-9.
45. Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol 2 005;162:8 9-1 00.
46. Brigham KS, Sandora TJ. Neisseria meningitidis: epidemiology, treatment and prevention in adolescents. Curr Opin Pediatr 2009;21:437-43.
47. Pichichero ME. Meningococcal conjugate vaccine in adolescents and children. Clin Pediatr (Phila) 2005;44:479-89. (Pubitemid 40967688)
48. Canada Communicable Disease Report:April 2009; Volume 36. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09pdf/acs-dcc-3.pdf (accessed 3 August 2009).
49. Granoff DM, Pollard AJ. Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr Infect Dis J 2007;26:716-22. (Pubitemid 47424642)
50. US Food and Drug Administration: Menveo® Highlights of Prescribing Information. February 2010. http://www.fda.gov/downloads/biologicsbloodvaccines/ vaccines/ approvedproducts/ucm201349.pdf (accessed 11 October2010).
51. Department of Health: Immunisation against infectious disease, 2006. http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/documents/ digitalasset/dh-116622.pdf (accessed on 21 June 2010).
52. Bayliss C, Bidmos F, Neal K, et al. A high prevalence of serogroup Y meningococcal isolates in students from the University of Nottingham. Poster presented at the 10th European Meningococci Disease Society (EMGM) Meeting, June 2009, Manchester, UK. http://emgm.eu/meetings/emgm2009/abstracts.pdf.
53. Health Protection Agency: Study to evaluate the immune response of United Kingdom (UK) infants receiving DTaP/Hib/IPV, meningococcal C conjugate and pneumococcal conjugate vaccines, antibody persistence and responses to booster doses in the second year of life. http://clinicaltrials.gov/ct2/show/ NCT00625677?te rm=meningococcal&cntry1=EU%3AGB&rank=1 (accessed 11 October 2010).
54. University of Oxford: Can we Reduce the Number of Vaccine Injections for Children? (MALTA) http://clinicaltrials.gov/ct2/show/NCT01129518?term= meningococcal&lea d=oxford&cntry1=EU%3AGB&rank=2 (accessed 12 July 2010).
55. Wallace LA, Bramley JC, Ahmed S, et al. Determinants of universal adolescent hepatitis B vaccine uptake. Arch Dis Child 2004;89:1041-2.
56. Joint Committee on Vaccination and Immunisation. Minutes of the meeting held on Wednesday 18 October 2006. London: Department of Health, 2006. www.advisorybodies.doh.gov.uk/jcvi/mins181006draft.htm (accessed 4 November 2009).
57. Banatvala J, Van Damme P, Emiroglu N. Hepatitis B immunisation in Britain: time to change? BMJ 2006;332:804-5.
58. Health Protection Agency: Recommendations for Hepatitis B vaccination of drug users in Liverpool and Sefton (November 2003) http://www.hpa.org.uk/web/ HPAwebFile/HPAweb-C/1194947370198 (accessed 4 November 2009).
59. Health Protection Agency: Immunization Coverage in Infants at Risk of Perinatal Transmission of Hepatitis B, 2006. http://www.hpa.org.uk/web/ HPAwebFile/ HPAweb-C/1217922474662 (accessed 14 November 2009).
60. Foundation for Liver Research. Hepatitis B: out of the shadows. London, 2004. www.ucl.ac.uk/liver-research/hepatitis-report.pdf (accessed 14 November 2009).
61. Department of Health: Joint Committee on Vaccination and Immunisation, 2010. http://www.dh.gov.uk/prod-consum-dh/groups/dh-digitalassets/@dh/@ab/ documents/digitalasset/dh-114124.pdf (accessed on 1 June 2010).
62. Boxall EH, A Sira J, El-Shuhkri N, et al. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis 2004;190:1264-9. (Pubitemid 39287752)
63. Pichichero ME. Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics 2009;124:1633-41.
64. Wheeler CM, Bautista OM, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 2008;26:686-96.